Recent advances in treatment of nodal and gastrointestinal follicular lymphoma

Table 8 Summary of clinical trials results of chimeric antigen receptor T-cell therapies

Study	Target disease	No. of patients	Objective response rate	Complete response rate	Progression-free survival	Overall survival	Adverse events and others	Ref.
Axicabtagene ciloleucel (Axi-cell), phase-II	r/r DLBCL, t-FL	n = 101	82%	40%	Unknown	52% (overall survival rate at 18.8 mo)	Neutropenia 78%; anemia 43%; thrombocytopenia 38%	[90]
Tisagenlecleucel (Tisa-cell), phase-II JULIET trial	r/r DLBCL	n = 93	52%	40%	65% (relapse-free survival rate)	Unknown	CRS 22%; neurologic events 12%; infections 20%	[91]
Axicabtagene ciloleucel (Axi-cell), phase-II	r/r iNHL (FL and MZL) after 2 or more treatment	n = 148, n = 124 (FL), n = 24 (MZL)	92%	74%	Unknown	Unknown	Serious adverse events (any grade) occurred in 50% of all	[93]
Tisagenlecleucel (Tisa-cell), phase-II ELARA trial	r/r FL (with 2 and more prior treatments)	n = 97	86.2%	69.1%	Unknown	Unknown	CRS 48.5% (> G3) neurological events 37.1% (> G3)	[96]
Lisocabtagene maraleucel (Liso-cell), phase-II	r/r large BCL	n = 61	80% (median follow-up 12.3 mo)	Unknown	Unknown	Unknown	Neutropenia 48%, thrombocytopenia 20%, CRS 38%	[99]

“Unknown” means data not shown, unknown information or not reached. r/r: Refractory and relapsed; FL: Follicular lymphoma; t-FL: Transformed follicular lymphoma; (i)NHL: (Indolent) non-Hodgkin lymphoma; DLBCL: Diffuse large B-cell lymphoma; BCL: B-cell lymphoma; MZL: Marginal zone lymphoma; CRS: Cytokine release syndrome.